Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T13:35:26.448Z.
Calculation as of: 2026-10-06T13:35:26.448Z.
Quote observation: 2026-10-06T13:31:50.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 237c69f2886ce95022375c2c4ca3b4be9bdf1b13d47079a179ac8fcd7ebd926e
PE RATIO
N/A
Market Cap
$17.07M
PE Ratio
N/A
TTM Avg
29275707116178676.00
3Y Avg
6105628756850110.00
5Y Avg
6105628756850110.00
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Allarity Therapeutics, Inc. (ALLR) | $15.91M | N/A | N/A | N/A | N/A |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $15.57M | N/A | N/A | N/A | N/A |
| Pasithea Therapeutics Corp. (KTTA)vs › | $15.35M | N/A | N/A | N/A | N/A |
| BioCardia, Inc. (BCDA)vs › | $16.37M | N/A | 42.19 | 43.76 | 41.41 |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.33M | N/A | 197.01 | 197.01 | 184.62 |
| Bionano Genomics, Inc. (BNGO)vs › | $16.57M | N/A | N/A | N/A | N/A |
| Lipocine Inc. (LPCN)vs › | $17.07M | N/A | 29275707116178676.00 | 6105628756850110.00 | 6105628756850110.00 |
| Dyadic International, Inc. (DYAI)vs › | $17.13M | N/A | 0.84 | 0.84 | 28.37 |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $14.03M | N/A | N/A | N/A | N/A |
| Vyome Holdings, Inc. (HIND)vs › | $13.76M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$1.00
Forward EPS (Est.)
$-0.80
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
